Article Text

AB0066 Clinical Usefulness of Serum Soluble ST2 in Rheumatoid Arthritis with Anti-TNF-α Therapy
  1. J.-J. Kim,
  2. J.-I. Choi,
  3. Y.-B. Joo,
  4. D.-H. Yoo
  1. Division Of Rheumatology, Department Of Internal Medicine, The Hospital for Rheumatic Disease, Hanyang University School of Medicine, Seoul, Korea, Republic Of


Background Rheumatoid arthritis (RA) is a chronic inflammatory disease leading to synovial proliferation as well as cartilage and bone destruction. Cytokine-mediated immunity plays an important role in the pathogenesis of RA. Over the last years, several studies suggested evidences that the interleukin-33 (IL-33) and its soluble ST2 (sST2) have functions in the inflammatory process that lead to arthritis. Especially, IL-33 was recognized to perform as an inflammatory cytokine, exerted profound effects in human RA and experimental inflammatory arthritis. Therefore, the targeting of IL-33 has been proposed as a potential therapeutic approach and serum marker of treatment for RA.

Objectives The aim of this study was to investigate the clinical significance of serum IL-33 and sST2 level according to anti-TNF-α therapy in RA.

Methods We included 24 RA patients who treated with TNF-α inhibitors in Hanyang University Hospital between 2010 and 2011. We collected demographic findings, laboratory findings such as white blood cell count (WBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and total arthritic joint counts before and 12 weeks after treatment of TNF-α inhibitors. And we measured serum IL-33 and sST2 by using enzyme-linked immunosorbent assay. Twenty-six healthy subjects used as a control group for the serum levels of IL-33 and sST2.

Results RA patients (23 females and 1 male; mean age 45.2±13.5 years, mean disease duration 91.3±75.3 months) were treated with etanercept (54.2%), adalimumab (37.5%) or infliximab (8.3%). The mean levels of serum IL-33 were 199.8±107.4 pg/mL of baseline in RA patients, 213.5±327.5 pg/mL in RA patients after 12 weeks with anti-TNF-α therapy and 107.4±184.4 pg/mL in healthy controls. And the mean levels of serum sST2 were 260.1±303.8 pg/mL in RA patients before anti-TNF-α therapy, 181.6±185.8 pg/mL in RA patients after 12 weeks anti-TNF-α therapy, and 83.62±70.2 pg/mL in healthy controls. There was no statistical significance of serum IL-33 level between RA patients and healthy controls. The serum sST2 levels in RA patients before and after anti-TNF-α therapy were significantly higher than in controls (P<0.05). Although serum sST2 level showed decreasing trend according to anti-TNF-α therapy, there was no statistically significant difference in sT2 levels between baseline and 12 weeks therapy. The serum sST2 level correlated positively with WBC (r=0.408, P=0.010), ESR (r=0.383, P=0.016) and CRP (r=0.585, P<0.001). However, it had no correlation with total arthritic joint counts. The responders (n=19) to anti-TNF-α therapy had higher levels of sST2 compared to non-responders (n=5) to anti-TNF-α therapy, but without statistical significance.

Conclusions The serum sST2 level was increased in RA patients, and correlated with other inflammatory markers of disease activity. Monitoring of serum sST2 levels may be a possible marker of effectiveness to anti-TNF-α therapy for RA patients, when this is supported by an extended study with more patients.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.4066

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.